"A Phase III Double-blind Randomised Study Assessing the Efficacy andSafety of Capivasertib + Paclitaxel Versus Placebo + Paclitaxel as First-lineTreatment for Patients with Histologically Confirmed, Locally Advanced(Inoperable) or Metastatic Triple-Negative Breast Cancer (TNBC)"
2020-07-04
عنوان الدراسة
"A Phase III Double-blind Randomised Study Assessing the Efficacy andSafety of Capivasertib + Paclitaxel Versus Placebo + Paclitaxel as First-lineTreatment for Patients with Histologically Confirmed, Locally Advanced(Inoperable) or Metastatic Triple-Negative Breast Cancer (TNBC)"
داعم الدراسة
AstraZeneca
دواء الدراسة
Capivasertib
رقم بروتوكول الدراسة
D3614C00001
حالة الدراسة
Ongoing
موقع الدراسة
King Fahad Specialist Hospital (Dammam), King Abdullah Medical City (Makkah), Specialized Medical Center (Riyadh)
مرحلة الدراسة
3
评论与建议
如对政府服务有任何咨询或意见,请填写所需信息。